Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
Prabha Shrestha(National Cancer Institute), Robert Yarchoan(National Cancer Institute), Yana Astter(Cancer Institute (WIA)), Ting Zhou(Memorial Sloan Kettering Cancer Center), Ramya Ramaswami(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Constance M. Yuan(National Cancer Institute), David A. Davis(University of Miami), Kathryn Lurain(The Ohio State University)
Cited by 12
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309